ESR1 and breast carcinoma: Motivated by ADCs, estrogen receptor (ER)-degrading PROTACs were conjugated to human epidermal growth factor receptor-2 (HER2)- or CD22-targeting monoclonal antibodies (mAbs) for the treatment of ER-positive breast cancers [98].